RxDoctor Payments Data

Amit Bahia, MD

Interventional Cardiology · Davenport, IANPI 1326010190

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (56.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Abbott at 43.6% of the total.

$8,440in general payments, 2019–2025

Across 74 payments — averaging $114.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • Terumo Medical Corporation$2K
  • Medtronic$1K
  • Edwards Lifesciences$724
  • Inari Medical, Inc.$262
  • Penumbra, Inc.$190
  • plus $776 from 11 others

What the payments were for

  • Travel & lodging$4,75256%
  • Food & beverage$3,61243%
  • Education$751%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,440 in reported general payments places this provider in the 65th percentile of 64 interventional cardiology providers in Iowa.

See all interventional cardiology providers in Iowa

Medicare billing

Part B allowed, 2024
$443,153
Medicare patients
1,227
Services billed
3,439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban391$377,852
EntrestoSacubitril/Valsartan176$186,796
XareltoRivaroxaban131$135,718
JardianceEmpagliflozin146$117,561
FarxigaDapagliflozin Propanediol178$109,675
Repatha SureclickEvolocumab87$71,343
BrilintaTicagrelor11$7,391
Metoprolol Succinate511$5,672
Atorvastatin Calcium793$5,525
Flecainide Acetate150$4,233
Dofetilide13$3,386
Ezetimibe145$3,145
Varenicline Tartrate11$3,018
Chlorthalidone166$2,829
Losartan Potassium408$2,676

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$21$117,561146 claims
AstraZenecaFarxiga, Brilinta$75$117,066189 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 64 interventional cardiology providers in Iowa.

Other interventional cardiology in Davenport

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →